| human | Q5 |
| P735 | given name | Karel | Q15731850 |
| Karel | Q15731850 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q36720362 | A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis |
| Q34156631 | Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial |
| Q33252484 | Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice |
| Q34145454 | Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease |
| Q35228055 | Assessment of histologic disease activity in Crohn's disease: a systematic review |
| Q28474993 | Atonal homolog 1 is a tumor suppressor gene |
| Q34231878 | Commentary: I see no convincing evidence of "enterocolitis," "colitis," or a "unique disease process". |
| Q35936315 | Crohn's disease and infections: a complex relationship. |
| Q35605834 | Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier |
| Q34610304 | Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series |
| Q35108807 | High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy |
| Q31148096 | Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices |
| Q33261882 | Immunosuppressive activity of a new pteridine derivative (4AZA1378) alleviates severity of TNBS-induced colitis in mice |
| Q37063113 | Indeterminate colitis: a review of the concept--what's in a name? |
| Q33766675 | Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease |
| Q36023527 | Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? |
| Q28592904 | Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation |
| Q35731494 | Medical therapy for Crohn's disease strictures |
| Q30945619 | Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment |
| Q34769969 | Neurotrophins and neurotrophin receptors in proliferative diabetic retinopathy |
| Q34410821 | Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial |
| Q36336481 | Pathology of early lower GI cancer |
| Q28255557 | Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease |
| Q35051849 | Role of chemokines in vernal keratoconjunctivitis |
| Q34612166 | T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status |
| Q36790612 | The role of chemokines and their receptors in uveitis |
| Q28216203 | The value of serologic markers in indeterminate colitis: a prospective follow-up study |
| Q30657855 | Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease |
Search more.